Evidence map›Paper›PMID 42830877›Full record

ArticleESMO real world data and digital oncology2026

Feasibility of a prospective real-time monitoring system capturing real-world data from elderly patients with acute myeloid leukemia.

S J F Hermans, J Versluis, S Langhout, E D van Werkhoven, G Huls, D Chitu, P E Westerweel, R B Fiets, L W Tick, A H E Herbers and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

S J F HermansDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
J VersluisDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
S LanghoutPerformation Healthcare Intelligence, Zeist, The Netherlands.
E D van WerkhovenDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
G HulsDepartment of Hematology, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
D ChituDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
P E WesterweelDepartment of Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
R B FietsDepartment of Hematology, Amphia Ziekenhuis, Breda, The Netherlands.
L W TickDepartment of Hematology, Maxima Medical Center, Veldhoven, The Netherlands.
A H E HerbersDepartment of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.
M F CorstenDepartment of Hematology, Meander Medisch Centrum, Amersfoort, The Netherlands.
D A BreemsDepartment of Hematology, ZNA Stuivenberg/Middelheim, Antwerp, Belgium.
I S NijhofDepartment of Hematology, Sint Antonius Ziekenhuis, Nieuwegein, The Netherlands.
M J CruijsenDepartment of Haematology-Oncology, Catherina Hospital, Eindhoven, The Netherlands.
Y SandbergDepartment of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands.
M DavidisDepartment of Hematology, Beatrix Hospital, Gorinchem, The Netherlands.
A KosterDepartment of Hematology, VieCuri Hospital, Venlo, The Netherlands.
K G van der HemDepartment of Hematology, Zaans Medical Center, Zaandam, The Netherlands.
L van der BurgDepartment of Internal Medicine, Antonius Hospital, Sneek, The Netherlands.
F BaboeDepartment of Internal Medicine, Bravis Hospital, Roosendaal, The Netherlands.
E F M PosthumaDepartment of Hematology, Reinier de Graaf Gasthuis, Delft, The Netherlands.
K SchadePerformation Healthcare Intelligence, Zeist, The Netherlands.
E BerkxDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
A G DinmohamedDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
P C HuijgensDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
J J CornelissenDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Real-world data (RWD) are increasingly applied as external controls in phase II-III clinical trials. However, retrospectively monitored RWD may suffer from limitations, including data availability and quality. Prospective monitoring of RWD may potentially overcome such limitations. We addressed the feasibility of an automated monitoring system for prospectively capturing RWD of older patients with acute myeloid leukemia (AML) and compared them with patients in the control arm of the HOVON-155 (H155) AML trial. Materials and methods: The system extracted predefined data from patients receiving nonintensive therapy in 10 Dutch hospitals. Patients in the RWD cohort were further selected for comparison with patients in the H155-trial by applying the trial eligibility criteria. Caliper propensity score matching (PSM) of patients in the RWD cohort with patients in the H155-control arm was performed based on age, European LeukemiaNet 2017, and Hematopoietic Cell Transplant-Comorbidity Index. Results: Between 2020 and 2025, 193 patients in the RWD cohort were identified, of whom 120 had not participated in the H155-trial but did meet its eligibility criteria. Patients in the H155 control arm ( Conclusion: A prospective RWD monitoring system was efficiently applied in 10 Dutch hospitals. Although patient characteristics initially differed from the H155 control arm, the outcome of the RWD cohort appeared similar following PSM. Prospective monitoring of RWD seems feasible but matching is needed for future use in clinical studies.

Indexed as

acute myeloid leukemiaexternal comparatorexternal control armexternal control cohortrandomized controlled trialreal-world data

Identifiers

PMID42830877
PMCPMC13634072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.